What is Aragen Bioscience?
Headquartered in Morgan Hill, California, Aragen Bioscience operates as a premier contract research organization (CRO) specializing in the complex lifecycle of biologic and diagnostic product development. The firm provides an extensive suite of in vitro and in vivo services, ranging from early-stage discovery and cell line development to sophisticated characterization and efficacy assessment. Through its integrated service model, Aragen Bioscience serves as a critical partner for organizations navigating the transition from laboratory research to clinical application, ensuring high-fidelity data and regulatory compliance throughout the development pipeline.
How much funding has Aragen Bioscience raised?
Aragen Bioscience has raised a total of $2.7M across 1 funding round:
Series B
$2.7M
Series B (2015): $2.7M, investors not publicly disclosed
Key Investors in Aragen Bioscience
Undisclosed Investor
An institutional capital provider focused on long-term growth and strategic development within the life sciences and healthcare services sectors.
Undisclosed Investor
A venture firm specializing in scaling high-growth biotechnology infrastructure and research-oriented service providers.
Undisclosed Investor
A corporate entity with a focus on enhancing the supply chain and research capabilities of the global pharmaceutical development ecosystem.
What's next for Aragen Bioscience?
With the recent infusion of capital, Aragen Bioscience is strategically positioned to accelerate its enterprise-level growth initiatives. The company is expected to prioritize the expansion of its laboratory facilities and the integration of advanced analytical technologies to enhance its biologic development throughput. As the demand for specialized outsourced research services continues to climb, Aragen is likely to focus on scaling its operational capacity to support larger, multi-phase clinical programs. This strategic trajectory suggests a focus on maintaining market leadership through technical innovation and the deepening of its service portfolio to address the evolving needs of the global biopharmaceutical industry.
See full Aragen Bioscience company page
